Serious adverse event - PDFSEARCH.IO - Document Search Engine

Serious adverse event
Results: 260

#	Item
81	SERIOUS, POSSIBLY ASSOCIATED AND UNEXPECTED ADVERSE EVENTS REPORTED FOR HUMAN GENE TRANSFER PROTOCOLS REPORTING PERIOD: [removed]/02 RECOMBINANT DNA ADVISORY COMMITTEE MEETING June 2002 Event # Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2013-12-10 13:06:27 Projectional radiography Pleural effusion Gene therapy Chest radiograph Ovarian cancer Chest Thoracentesis Medicine Biology Thorax
82	SERIOUS, POSSIBLY ASSOCIATED AND UNEXPECTED ADVERSE EVENTS REPORTED FOR HUMAN GENE TRANSFER PROTOCOLS REPORTING PERIOD: [removed]/02 RECOMBINANT DNA ADVISORY COMMITTEE MEETING March 2002 Event ID OBA Date Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2013-12-10 13:03:37 Design of experiments Pharmaceutical industry Brain tumor Glioblastoma multiforme Clinical research
83	SERIOUS, POSSIBLY ASSOCIATED AND UNEXPECTED ADVERSE EVENTS REPORTED FOR HUMAN GENE TRANSFER PROTOCOLS REPORTING PERIOD: [removed]/01 RECOMBINANT DNA ADVISORY COMMITTEE MEETING June 2001 Event # Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2014-01-14 11:18:33 Clinical research Design of experiments Eli Lilly and Company Ketones Clinical trial Chemotherapy Prostate cancer Melanoma Methadone Medicine Health Cancer treatments
84	SERIOUS, POSSIBLY ASSOCIATED AND UNEXPECTED ADVERSE EVENTS REPORTED FOR HUMAN GENE TRANSFER PROTOCOLS REPORTING PERIOD: [removed]/01 RECOMBINANT DNA ADVISORY COMMITTEE MEETING December 2001 Event Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2013-12-10 13:02:15 Health Cytokines Hematology Microbiology Vaccine Virology Granulocyte macrophage colony-stimulating factor Pericardial effusion Biology Vaccination Medicine
85	DF/HCC Protocol[removed]Serious Adverse Event Analysis Glenn Dranoff Dana-Farber Cancer Institute Overview Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2013-12-31 11:45:47 Transplantation medicine Stem cells Hematopoietic stem cell transplantation Lymphatic system Surgical oncology Granulocyte macrophage colony-stimulating factor Acute myeloid leukemia Immunotherapy Graft-versus-host disease Medicine Biology Hematology
86	Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates [Posted[removed]AUDIENCE: Pharmacy, Patient, Health Professional, Nursing ISSUE: Hospira, Inc. will initiate a voluntary recall of one lot of 1% Add to Reading List Source URL: www.cnyems.org Language: English - Date: 2014-12-02 08:29:44 Food and Drug Administration Pharmaceutical industry MedWatch Clinical research Serious adverse event Hospira Lidocaine Pharmacology Medicine Pharmaceutical sciences
87	SERIOUS, POSSIBLY ASSOCIATED AND UNEXPECTED ADVERSE EVENTS REPORTED FOR HUMAN GENE TRANSFER PROTOCOLS REPORTING PERIOD: [removed]/02 RECOMBINANT DNA ADVISORY COMMITTEE MEETING September 2002 Event # Add to Reading List Source URL: osp.od.nih.gov Language: English - Date: 2013-12-10 13:09:47 Cell biology Gynaecological cancer Ovarian cancer Cell culture Vascular endothelial growth factor Adenocarcinoma Stem cell Cancer Biology Medicine Biotechnology
88	Serious adverse events associated with paediatric complementary and alternative medicine Principal investigator Co-investigators Add to Reading List Source URL: www.cpsp.cps.ca Language: English - Date: 2012-10-22 14:28:30 Clinical research Pharmaceutical industry Chiropractic Adverse event Veterinary chiropractic Spinal manipulation Epidemiology Advanced Encryption Standard Medicine Health Alternative medicine
89	F10.0000 UK External Prompt Reporting Form Add to Reading List Source URL: www.research.uky.edu Language: English - Date: 2014-03-10 14:57:55 Science Pharmacology Ethics Design of experiments Drug safety Adverse event Serious adverse event Institutional review board Clinical trial Clinical research Pharmaceutical industry Research
90	Adverse Events Policy and Reporting Guidelines The Queen’s University and Affiliated Teaching Hospitals Health Sciences Research Ethics Board (REB) has developed a policy with reporting requirements for Serious Adverse Add to Reading List Source URL: www.queensu.ca Language: English - Date: 2014-11-04 15:10:37 Adverse event Clinical research Pharmaceutical industry Serious adverse event

UPDATE